Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b combined vaccine
- Development stage
- Unknown
- Lead developer
- Beijing Zhifei Lvzhu Biopharmaceutical
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
The Haemophilus influenzae type B combined vaccine is a combination immunization product that includes the Haemophilus influenzae type b (Hib) conjugate vaccine along with one or more other vaccines, such as diphtheria, tetanus, pertussis (DTaP), hepatitis B, and/or inactivated poliovirus. The Hib component is made from the purified polysaccharide capsule of H. influenzae type b bacteria linked to a carrier protein (conjugate), which enhances immune response in young children. The primary mechanism of action is to induce immunity against invasive Hib disease by stimulating the production of antibodies targeting the bacterial polysaccharide capsule. Combination formulations reduce the number of injections required for routine childhood immunization schedules and are widely used globally[3][7]. These vaccines are recommended for infants and young children to prevent serious diseases such as meningitis, pneumonia, epiglottitis, sepsis, and other invasive infections caused by H. influenzae type b[1][2][4].
- Other names
- Hib combined vaccineHaemophilus influenzae type b conjugate combination vaccine
02
Targets
Diphtheria toxinHBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)PV3 (Sabin) (Poliovirus type 3 antigen)
Beyond the preview
Go deeper on haemophilus influenzae type b combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b combined vaccine.